Choreo LLC Acquires 5,123 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Choreo LLC lifted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 29.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,274 shares of the life sciences company’s stock after acquiring an additional 5,123 shares during the period. Choreo LLC’s holdings in Integra LifeSciences were worth $500,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after buying an additional 1,120 shares in the last quarter. Northwest Investment Counselors LLC bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $73,000. Nisa Investment Advisors LLC grew its stake in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares in the last quarter. Centiva Capital LP bought a new stake in Integra LifeSciences during the 3rd quarter worth approximately $192,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences in the 3rd quarter worth approximately $198,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on IART shares. Citigroup boosted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley started coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Price Performance

IART opened at $25.68 on Wednesday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.98 billion, a P/E ratio of -285.30, a PEG ratio of 0.87 and a beta of 1.17. The stock has a 50-day moving average price of $23.85 and a 200-day moving average price of $21.84. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.10% of the stock is owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.